Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer

<p>Supplementary Table S2. Results of single-sample gene set enrichment analysis (ssGSEA) of transcriptomic profiles from HCC-1428 and HCC-1428/LTED cells.</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Nicole A. Traphagen (16677391) (author)
Daljnji autori:	Gary N. Schwartz (16005870) (author), Steven Tau (16677394) (author), Alyssa M. Roberts (16677397) (author), Amanda Jiang (15117790) (author), Sarah R. Hosford (16677400) (author), Jonathan D. Marotti (16005879) (author), Abigail E. Goen (16677403) (author), Bianca A. Romo (16677406) (author), Anneka L. Johnson (16677409) (author), Emily-Claire K. Duffy (16677412) (author), Eugene Demidenko (16005894) (author), Paul Heverly (16677415) (author), Yaron Mosesson (16677418) (author), Shannon M. Soucy (16005888) (author), Fred Kolling (16005891) (author), Todd W. Miller (16005897) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Breast Cancer Drug Mechanisms Cellular responses to anticancer drugs Drug Resistance Reversal of drug resistance
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
od: Nicole A. Traphagen (16677391)
Izdano: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
od: Alex C.H. Liu (14961921)
Izdano: (2025)

Supplementary Data from Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor–Positive Breast Cancer
od: Lixuan Wei (14962431)
Izdano: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
od: Dahihm Kim (16546203)
Izdano: (2025)

Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
od: Juliana Navarro-Yepes (17079059)
Izdano: (2025)

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
od: Ossia M. Eichhoff (14964145)
Izdano: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
od: Yufang Bao (15386826)
Izdano: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
od: Kavya Ramkumar (16474203)
Izdano: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
od: Milana A. Bergamino (15038015)
Izdano: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
od: Fang Wei (15057172)
Izdano: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
od: Fang Wei (15057172)
Izdano: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
od: Fang Wei (15057172)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_vdvfg0it3b3msv40nl7rp6qbv5